Cartesian Therapeutics Chair Carrie Cox resigns; CEO Carsten Brunn named Chairman, bylaw amended

Cartesian Therapeutics, Inc.

Carrie Cox resigned from the Board and as Chair on Oct. 29, 2025, to focus on other commitments; not related to any disagreement.
Carsten Brunn, Ph.D., CEO and Board member, appointed Chairman of the Board effective immediately.
Patrick Zenner named Lead Independent Director; Kemal Malik appointed Chairman of the Compensation Committee.
Board approved amended and restated Bylaws to incorporate references to Lead Independent Director.

item 5.02 item 5.03 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001140361-25-039793
form_type: 8-K
ticker: RNAC
cik: 0001453687
company_name: Cartesian Therapeutics, Inc.
filed_at: 2025-10-30T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.444244+00:00
generated_at: 2026-05-17T01:18:34.790043+00:00
sec_items: ["5.02", "5.03", "7.01", "9.01"]
event_type: leadership
sentiment: neutral
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001140361-25-039793
json_url: https://secwatch.observer/filing/0001140361-25-039793.json
markdown_url: https://secwatch.observer/filing/0001140361-25-039793.md
text_url: https://secwatch.observer/filing/0001140361-25-039793.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1453687/000114036125039793/0001140361-25-039793-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1453687/000114036125039793/ef20057980_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001140361-25-039793

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.